Astrocyte dysfunction has previously been linked to multiple neurodegenerative disorders including Parkinson’s disease (PD). Among their many roles, astrocytes are mediators of the brain immune response, and astrocyte reactivity is a pathological feature of PD. They are also involved in the formation and maintenance of the blood-brain barrier (BBB), but barrier integrity is compromised in people with PD. This study focuses on an unexplored area of PD pathogenesis by characterizing the interplay between astrocytes, inflammation and BBB integrity, and by combining patient-derived induced pluripotent stem cells with microfluidic technologies to generate a 3D human BBB chip. Here we report that astrocytes derived from female donors harboring the PD-related LRRK2 G2019S mutation are pro-inflammatory and fail to support the formation of a functional capillary in vitro. We show that inhibition of MEK1/2 signaling attenuates the inflammatory profile of mutant astrocytes and rescues BBB formation, providing insights into mechanisms regulating barrier integrity in PD. Lastly, we confirm that vascular changes are also observed in the human postmortem substantia nigra of both males and females with PD.
INTRODUCTION: Metabolic disorders are risk factors for Alzheimer's disease (AD), although underlying mechanisms remain unclear. We investigated the relationship between peripheral metabolic markers – adiponectin, fibroblast growth factor 21 (FGF‐21), and insulin‐like growth factor binding protein 2 (IGFBP‐2) – and AD. METHODS: Participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, and cognitively healthy (CH) controls were from the Consortium for the Early Identification of Alzheimer's Disease–Quebec cohort ( n = 287). Serum adiponectin, FGF‐21, and IGFBP‐2 concentrations were measured, compared between groups, and assessed for associations with clinical, cognitive, biochemical, and magnetic resonance imaging (MRI) data. RESULTS: Metabolic dysfunction was linked to lower adiponectin and IGFBP‐2, but higher FGF‐21. Both FGF‐21 and IGFBP‐2 increased with age and were inversely associated with cognitive performance. IGFBP‐2 was elevated at SCD stage and correlated with plasma tau phosphorylated at threonine 181 and amygdala atrophy. Adiponectin was unrelated to cognition. DISCUSSION: These findings suggest that IGFBP‐2 and, to a lesser extent, FGF‐21 may serve as early biomarkers of cognitive impairment, reflecting intricate links between peripheral dysmetabolism and AD.
STRUCTURED Introduction: Metabolic disorders are risk factors for Alzheimer’s disease (AD), although underlying mechanisms remain unclear. We investigated the relationship between peripheral metabolic markers – adiponectin, FGF-21 and IGFBP-2 – and AD. Methods: Participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD and cognitively healthy controls (CH) were from the CIMA-Q cohort (n=287). Serum adiponectin, FGF-21, and IGFBP-2 concentrations were measured, compared between groups, and assessed for associations with clinical, cognitive, biochemical and MRI data. Results: Metabolic dysfunction was linked to lower adiponectin and IGFBP-2, but higher FGF-21. Both FGF-21 and IGFBP-2 increased with age and were inversely associated with cognitive performance. IGFBP-2 was elevated at SCD stage and correlated with plasma pTau181 and amygdala atrophy. Adiponectin was unrelated to cognition. Discussion: These findings suggest that IGFBP-2, and FGF-21 to a lesser extent, may serve as early biomarkers of cognitive impairment, reflecting intricate links between peripheral dysmetabolism and AD.
INTRODUCTION: We evaluated associations between phosphorylated au 217 (p‐tau217), p‐tau181, p‐tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p‐tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease–Quebec (CIMA‐Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p‐tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p‐tau217 in cognitively impaired individuals ( β = ‐0.49, p < 0.001). Hypertension was further linked to steeper memory and executive function decline ( β = −0.10, both p = 0.04) in this group, and it amplified the effect of p‐tau217 on cognitive decline across the whole group. Higher p‐tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p‐tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.